Five-year survival outcomes by NPM1 mutation status (n = 134 patients)
| . | Overall . | Censored at HCT in 1st CR . | ||||
|---|---|---|---|---|---|---|
| . | NPM1mut (n = 79) . | NPM1WT (n = 55) . | P . | NPM1mut (n = 79) . | NPM1WT (n = 55) . | P . |
| OS, estimates at 5 y (95% CI), % | 69.8 (60.2-80.9) | 45.7 (34.1-61.3) | .003 | 82.6 (72.9-93.5) | 56.8 (38.0-84.8) | .015 |
| EFS, estimates at 5 y (95% CI), % | 48.4 (38.4-61) | 24.6 (15.3-39.4) | .003 | 50.7 (39.7-64.6) | 26.4 (15.3-45.5) | .007 |
| DFS, estimates at 5 y (95% CI), % | 69.5 (58.9-81.9) | 50.3 (36.6-69.1) | .001 | 70.5 (57.8-86.1) | 44.9 (27.2-74.1) | .015 |
| CIR, estimates at 5 y (95% CI), % | 21.0 (20.1-21.9) | 44.5 (43.1-45.9) | .006 | 22.0 (21.3-22.6) | 34.8 (33.2-36.3) | .030 |
| . | Overall . | Censored at HCT in 1st CR . | ||||
|---|---|---|---|---|---|---|
| . | NPM1mut (n = 79) . | NPM1WT (n = 55) . | P . | NPM1mut (n = 79) . | NPM1WT (n = 55) . | P . |
| OS, estimates at 5 y (95% CI), % | 69.8 (60.2-80.9) | 45.7 (34.1-61.3) | .003 | 82.6 (72.9-93.5) | 56.8 (38.0-84.8) | .015 |
| EFS, estimates at 5 y (95% CI), % | 48.4 (38.4-61) | 24.6 (15.3-39.4) | .003 | 50.7 (39.7-64.6) | 26.4 (15.3-45.5) | .007 |
| DFS, estimates at 5 y (95% CI), % | 69.5 (58.9-81.9) | 50.3 (36.6-69.1) | .001 | 70.5 (57.8-86.1) | 44.9 (27.2-74.1) | .015 |
| CIR, estimates at 5 y (95% CI), % | 21.0 (20.1-21.9) | 44.5 (43.1-45.9) | .006 | 22.0 (21.3-22.6) | 34.8 (33.2-36.3) | .030 |
Significant differences are indicated in bold.